BRCA1/2 — Targeted Therapies, Trials & Pipeline

BRCA1/2 mutations confer homologous-recombination deficiency and synthetic-lethal sensitivity to PARP inhibition.

Approved drugs targeting BRCA1/2

Investigational pipeline agents

Landmark trials